Friedreich ataxia (FA)
About
FA is the most common hereditary ataxia caused by repeated amplification of the GAA trinucleotide of the FXN gene, resulting in a deficiency of frataxin protein. Core dilemmas: ① There is currently no effective treatment to prevent disease progression;② Although Omaveloxolone has been approved, its effect is limited;③ Cardiomyopathy is the main cause of death;④ Gene therapy is in early clinical trials.
Features & Symptoms
- FXN gene mutation
- GAA trinucleotide repeat amplification
- progressive ataxia
- Cardiomyopathy and diabetes
Treatment Options
| Treatment | Description | Stage | Price Range |
|---|---|---|---|
| Omaveloxolone（Skyclarys） | Nrf2 activator, approved by the FDA in 2023, is the first approved FA treatment that partially improves neurological symptoms. | FDA批准 | $400K - $800K/年 |
| Gene therapy (AAV-FXN) | AAV vectors that deliver normal FXN genes are currently in clinical trials. | Phase I/II | $1M - $2.5M/次（一次性） |
| Comprehensive rehabilitation management | Including comprehensive programs such as physical therapy, cardiac monitoring, diabetes management, and scoliosis monitoring. | 临床应用 | $80K - $200K/年 |
Prognosis
Died 15-20 years after the onset, mainly due to cardiomyopathy
Additional Notes
Notes: Cardiac monitoring: Hypertrophic or dilated cardiomyopathy is the main cause of death and requires regular cardiac ultrasound and electrocardiogram examinations; Diabetes screening: About 10-20% of patients will develop diabetes and require regular oral glucose tolerance tests; Scoliosis management: Scoliosis needs to be regularly evaluated and orthopedic treatment; Omaveloxlone: has been approved for FA to improve neurological function and is currently the only approved disease modification therapy; Hearing monitoring: Sensorineural deafness is common and requires regular hearing examinations.; Exclusive service commitment: The platform will allocate a dedicated medical team to each patient to assist in dismantling and properly deploying the following precautions throughout the process. When cross-state and cross-border diagnosis and treatment projects or drugs are involved, the platform will make overall arrangements for the entire docking; for disabled and semi-disabled patient groups, the platform will provide rush-free alternative solutions (including remote consultation, door-to-door sampling, direct drug delivery in the cold chain, etc.), to ensure that patients can get the same high-quality diagnosis and treatment resources without having to travel in person.; Study phase: FDA approval. Prognosis: Death 15-20 years after the onset, mainly due to cardiomyopathy.
Frequently Asked Questions
What is Friedreich ataxia (FA)?
FA is the most common hereditary ataxia caused by repeated amplification of the GAA trinucleotide of the FXN gene, resulting in a deficiency of frataxin protein. Core dilemmas: ① There is currently no effective treatment to prevent disease progression;② Although Omaveloxolone has been approved, its effect is limited;③ Cardiomyopathy is the main cause of death;④ Gene therapy is in early clinical trials.
What are the symptoms of Friedreich ataxia (FA)?
FXN gene mutation,GAA trinucleotide repeat amplification,progressive ataxia,Cardiomyopathy and diabetes
How is Friedreich ataxia (FA) treated?
Omaveloxolone（Skyclarys）: Nrf2 activator, approved by the FDA in 2023, is the first approved FA treatment that partially improves neurological symptoms.; Gene therapy (AAV-FXN): AAV vectors that deliver normal FXN genes are currently in clinical trials.; Comprehensive rehabilitation management: Including comprehensive programs such as physical therapy, cardiac monitoring, diabetes management, and scoliosis monitoring.
What is the prognosis for Friedreich ataxia (FA)?
Died 15-20 years after the onset, mainly due to cardiomyopathy